| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
The claim database was obtained from JMDC. Between January 2005 and July 2017, there were 5,767 patients diagnosed prostate cancer. The total number of hospitals was 17,001, of which 14,487 (85.2%) were clinics with 0-19 beds. The total number of medical prescriptions was 1,426,115. Among them, the drugs used for the treatment of prostate cancer, 4,288 cases of Leuplin, 4,220 cases of Casodex tablets (6,680 generic products), 3,155 cases of Zoradex, and 1,028 cases of Odyne tablets (424 generic products). The total number of laboratory tests was 5,225,046, with Creatinine 91,672, AST 85,736, ALT 85,523, and PSA 7,877. It was considered that this large-data could be used to estimate the risk of adverse events occurring in renal and liver functions.
|
